GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of why does nobody talk about ACHIEVE — 22 comments in the full submission. View in context.
465
c/orforglipron·submitted 22 days ago by u/taper_off_tabitha

why does nobody talk about ACHIEVE

Questionbranch of 6 comments

why does nobody talk about ACHIEVE — that is what I am asking, and I have already read the wiki twice. Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different. Nothing containing this compound is approved by…

Read the full submission and all 22 comments →

This branch

6 comments, started 21 days ago
u/incretin_ivyMOD26 points·21 days ago

Left up. It is careful about what is peptide and what is not, which is more than most threads here manage.

replysharereportpermalink
u/hazard_ratio_halstats12 points·20 days ago

the manufacturing story is genuinely different from the injectables

replysharereportpermalink
u/yannick_salinas17 points·20 days ago

Small fix — the two programme names got swapped upthread and it changes which population the figure came from.

replysharereportpermalink
u/incretin_ivypharmacology21 points·20 days ago

daily dosing changes adherence in both directions

replysharereportpermalink
u/discount_math_dm7 points·20 days ago

Push back: daily dosing is not automatically better adherence. It is a different failure mode, not a solved problem.

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/orforglipron
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/phase_two_peteu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →